Examining both genetics and epigenetics is crucial for understanding the underlying mechanisms behind disease development and progression. Scientists have determined that alterations to DNA methylation patterns, including 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) residues, can serve as early indicators of diseases such as cancer and neurological disorders. However, many methods cannot simultaneously analyze genetic information and distinguish between 5mC and 5hmC marks.
Download this poster to learn how an innovative multimodal solution empowers researchers to both sequence the genome and differentiate 5mC from 5hmC marks from a single DNA sample, thereby enabling the discovery of novel disease biomarkers.
